Announcements Trials
Browse Landscape

Phase

Phase 2 74Phase 1/2 44Phase 1 24Phase 3 21Phase NA 3Phase 4 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Pathologic Processes 1Neoplasms 1Myelodysplastic Syndromes 1Hematologic Diseases 1Bone Marrow Diseases 1

Interventions

Saline Solution 10Docetaxel 10Bevacizumab 9nilotinib 8enzalutamide 8Paclitaxel 8Letrozole 8Fentanyl 8Everolimus 8Cyclophosphamide 8Carboplatin 8Bupivacaine 8Lidocaine 7Sodium Chloride 6Oxycodone 6Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 6Erlotinib Hydrochloride 6Dexamethasone 6Capecitabine 6Trastuzumab 5Tobacco Use Cessation Devices 5Surveys and Questionnaires 5Nivolumab 5Hydromorphone 5Adalimumab 5fludarabine 4Zoledronic Acid 4Tranexamic Acid 4Tacrolimus 4Rocuronium 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Has results × Azacitidine × Clear all
NCT01201811 2019-12-05

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Celgene

Phase 4 Completed
44 enrolled 26 charts
Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myelodysplastic Syndromes, Neoplasms, Pathologic Processes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡